Effects of Atorvastatin Versus Pravastatin on Platelet Inhibition by Clopidogrel
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00405717|
Recruitment Status : Completed
First Posted : November 30, 2006
Last Update Posted : November 7, 2008
Clopidogrel and statins are frequently coadministered in patients with ischemic heart diseases. Recent reports suggested that clopidogrel's effectiveness in inhibiting adenosine diphosphate (ADP)-induced platelets aggregation is attenuated by co-administration of certain statins. The objective of the present study is to define which kind of statins might interfere with the antiaggregation property of clopidogrel in patients with acute coronary Syndrome after percutaneous coronary intervention (PCI).
In this prospective randomized study, all patients in test group will receive clopidogrel plus atorvastatin, and all patients in control group will receive clopidogrel plus pravastatin. All patients will be followed up for one year. The primary endpoints include death, non fatal AMI, urgent revascularization. The secondary endpoints include hemorrhage events and subacute thrombosis events at 1 year.
|Condition or disease||Intervention/treatment||Phase|
|Ischemic Heart Disease Acute Coronary Syndromes||Drug: atorvastatin,pravastatin||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||1300 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Effects of Atorvastatin Versus Pravastatin on Platelet Inhibition by Clopidogrel in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention|
|Study Start Date :||February 2006|
|Actual Primary Completion Date :||May 2008|
|Actual Study Completion Date :||May 2008|
- major adverse cardiac and cerebral events at 1 year [ Time Frame: 1 year ]
- hemorrhage events and subacute thrombosis events at 1 year [ Time Frame: 1 year ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00405717
|Shenyang, Liaoning, China|
|Principal Investigator:||Yaling Han, M.D.||Shenyang Northern Hospital|